Effect of Strontium-89 on painful bone metastases in zoledronic acid received patients with prostate cancer

Effect of Strontium-89 on painful bone metastases in zoledronic acid received patients with prostate cancer - Effect of Strontium-89 on painful bone metastases in zoledronic acid received patients with prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004718

Enrollment

Registered

2010-12-20

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Diagnosis of prostate cancer was confirmed 2. Stage D (with bone metastasis) prostate cancer 3. Case with tumor marker positive and history of hormonal therapy and that have been receiving zoledronic acid for at least a month. 4. ECOG performance status 0-2 5 Case with multiple bone metastases demonstrated on standard bone scintigraphy, with bone pain localized in the areas of higher up-take. 6. Case with using analgesic such as NSAIDs or opioid for painful bone metastases 7. WBC>3,000/mm3, neutrophil>1,500/mm3, platelet>75,000/mm3, Hb>9.0g/dL, and at a case after chemotherapy or external radiotherapy, the nadir of each parameter is confirmed. 8.Case that DIC is excluded and with no rapid decrease in platelet count 9. Case that survival more than 1 month is anticipated 10.Case signed informed consent of the patients for the registration

Exclusion criteria

Exclusion criteria: 1. Patients with severe renal failure 2. Patients with ongoing chemotherapy 3. Patients with ongoing external radiotherapy 4. Patients with unmanageable urinary incontinence 5. Patients with severe complication 6. Patients with history of drug allergy that are considered inappropriate to conduct this trial 7. Other patients deemed not appropriate for study entry by the investigator

Design outcomes

Primary

Measure	Time frame
Response rate (the ratio of responder to bone pain)	—

Secondary

Measure	Time frame
Safety and mechanism(changes in the level of tumor marker and bone turnover marker)	—

Countries

Japan

Contacts

Public ContactHirohiko Nagata

Keio University Shool of Medicine Department of Urology

hironagata-jua@umin.ac.jp03-3353-1211

Outcome results